Tesamorelin results: what the clinical research actually shows

Last updated 2026-07-24

What is tesamorelin actually approved for?

Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analogue, sold under the brand name Egrifta, and it is FDA-approved for exactly one thing: reducing excess visceral adipose tissue in HIV-infected patients with lipodystrophy ^[1]. That's it. It is not approved for weight loss in the general population, not approved for age-related GH decline, and not approved as a bodybuilding or anti-aging aid. The drug works by stimulating the pituitary gland to release growth hormone in a pattern that mimics the body's natural pulsatile secretion, rather than flooding the system with GH directly ^[2]. That distinction matters clinically: GHRH analogues preserve a level of feedback regulation that straight GH injections bypass. HIV-associated lipodystrophy is a specific, recognized clinical syndrome, more than generic belly fat. It involves fat redistribution, often visceral fat gain combined with peripheral fat loss, tied to antiretroviral therapy and the disease process itself ^[3]. That's the population every major trial enrolled, and it's the population the label covers. Anyone using tesamorelin outside that indication, including people without HIV who want visceral fat reduction or GH support, is using it off-label. That's legal for a physician to prescribe, but it means the trial evidence doesn't directly apply to you. More on what that means for interpreting the numbers below.

What did the phase 3 trials actually measure?

The core approval evidence comes from two multicenter, double-blind, placebo-controlled phase 3 trials in HIV patients with excess abdominal fat, pooled and analyzed together with safety extension data ^[4]. Both trials ran the same basic design: tesamorelin 2 mg by daily subcutaneous injection versus placebo, with visceral adipose tissue (VAT) measured by CT scan as the primary endpoint. The headline result: tesamorelin reduced visceral fat by roughly 18% relative to placebo over 26 weeks in the pooled phase 3 analysis ^[4]. That's a real, statistically significant effect on a CT-measured hard endpoint, not a self-reported outcome. A 2026 meta-analysis of randomized controlled trials confirmed consistent visceral fat and hepatic fat reductions across the tesamorelin trial base, alongside a defined safety profile ^[5]. Secondary endpoints tracked things like triglycerides, and later trials added liver fat content by MRI or biopsy. The safety extension portion of the pooled analysis also gave a longer look at what happens with continued use, which matters because lipodystrophy management is a long-term problem, not a six-month fix ^[4]. Worth saying plainly: these are the trials the FDA approval rests on. When you see tesamorelin discussed anywhere, this pooled phase 3 dataset is the evidence spine everything else hangs off of.

How much visceral fat does tesamorelin actually remove?

Around 18% relative reduction in visceral adipose tissue versus placebo over 26 weeks, based on the pooled phase 3 program in HIV-associated lipodystrophy ^[4]. That's measured by CT, which is a harder endpoint than waist circumference or scale weight. A separate 2021 analysis looked past the raw quantity number and asked about fat quality, finding that tesamorelin improved adipose tissue quality (things like fat density and distribution patterns) independent of how much total fat mass changed ^[6]. That's a subtler finding worth knowing: the benefit isn't purely about the number on the CT scan, it's also about what kind of fat remains. A 2023 post hoc analysis of the phase 3 data looked at whether people with or without dorsocervical fat pads (the 'buffalo hump' sometimes seen in HIV lipodystrophy) responded differently, and found effects held up in both subgroups ^[7]. That's useful for clinicians deciding who's a reasonable candidate. What the trials don't tell you: how much visceral fat drops in someone without HIV, someone using tesamorelin purely for body composition goals, or someone on a modified dosing schedule. Those questions haven't been answered by controlled trials at anything like this scale.

Does tesamorelin help with liver fat and NAFLD?

There's a genuine secondary evidence base here, and it's more interesting than the visceral fat headline in some ways. A randomized, double-blind, multicenter trial published in The Lancet HIV tested tesamorelin specifically for non-alcoholic fatty liver disease in HIV patients and found meaningful reductions in liver fat content ^[8]. A separate study tied visceral fat reduction directly to improved liver enzyme levels in HIV patients on tesamorelin, suggesting the VAT drop isn't just cosmetic, it tracks with a downstream metabolic benefit ^[9]. Follow-up mechanistic work has tried to explain why: a 2020 JCI Insight paper mapped hepatic transcriptomic signatures after tesamorelin treatment ^[10], and a 2021 Scientific Reports study used proteomic and transcriptomic profiling to trace the biological pathways behind the liver fat response ^[11]. None of this constitutes an FDA-approved indication for NAFLD. It's legitimate research signal in a population (HIV patients with metabolic complications) where liver fat is a recognized problem, but it hasn't translated into a labeled use. If you're reading this because you're worried about fatty liver and not living with HIV, the honest answer is that this evidence doesn't transfer cleanly to you.

What happens to inflammation and metabolic markers?

A 2011 study in AIDS examined inflammatory markers in HIV patients with excess abdominal fat on tesamorelin and found reductions that correlated with the degree of visceral fat loss . That's a coherent story: less visceral fat, less of the inflammatory signaling visceral adipose tissue is known to produce. Triglycerides were tracked as a secondary endpoint across the phase 3 program, with reported improvements alongside the VAT reduction ^[4]. This lines up with the general metabolic profile of visceral fat: it's more inflammatory and more metabolically active than subcutaneous fat, so shrinking it tends to move several markers in the right direction simultaneously. What's less settled is neurocognitive effects. A 2025 study in The Journal of Infectious Diseases examined tesamorelin's effects on neurocognitive impairment in people with HIV and abdominal obesity ^[12]. This is an active area, not a closed case, and it's a good example of where tesamorelin research is expanding beyond the original visceral fat indication without yet producing a new approved use.

Does tesamorelin still work with modern HIV drugs (integrase inhibitors)?

This is a legitimate and fairly recent question, because the antiretroviral landscape has shifted a lot since the original phase 3 trials. Integrase strand transfer inhibitors are now standard first-line therapy for HIV, and they carry their own weight-gain and metabolic profile that differs from older regimens. A 2024 study in AIDS specifically evaluated the efficacy and safety of tesamorelin in people with HIV on integrase inhibitor-based regimens ^[13]. This matters because if the metabolic background has changed, older trial data (largely run before integrase inhibitors dominated) might not fully generalize. The fact that researchers went back and tested this combination directly is a sign the field takes that concern seriously rather than assuming old data still applies unchanged. If you're on a modern integrase-inhibitor regimen and considering tesamorelin, this is the study your prescriber should be aware of, since it's the most direct evidence for that specific combination.

How is tesamorelin dosed in the trials, and does that match real-world use?

The approved and trial dosing is 2 mg tesamorelin by subcutaneous injection once daily ^[4]. A 2015 population pharmacokinetic analysis modeled tesamorelin exposure across HIV-infected patients and healthy subjects, characterizing how absorption and clearance behave across different populations and helping explain some of the variability in individual response ^[14]. Daily dosing is a real burden. It's not a once-weekly peptide, and that adherence demand shows up as a practical barrier outside tightly monitored trial conditions. For a full walkthrough of injection sites, timing, and how clinicians handle missed doses, see our tesamorelin dosage guide, and if you're calculating volumes from a vial, the tesamorelin dosage calculator and reconstitution guide cover the practical math. One thing the pharmacokinetic literature flags: individual variability in response is real, and it's part of why some patients see a strong visceral fat response and others see a modest one at the same nominal dose ^[14]. That's not unique to tesamorelin, but it's worth knowing before assuming the trial average applies to any one person.

What are the real safety risks, based on the trial data?

The safety data comes primarily from the phase 3 program's extension phase, which followed patients on tesamorelin for longer than the initial 26-week efficacy window ^[4]. Injection site reactions are the most consistently reported issue. Joint-related complaints and swelling (arthralgia, peripheral edema) also show up as GH-axis-related side effects, consistent with what's expected from stimulating growth hormone release. Because tesamorelin raises GH and downstream IGF-1, there's a legitimate concern about glucose metabolism, and this gets monitored in trials and in clinical practice. The Journal of Clinical Endocrinology and Metabolism review on lipodystrophy management discusses this monitoring need as part of the broader clinical picture for these patients ^[3]. For the complete rundown of adverse events reported in trials, frequency data, and who should avoid tesamorelin entirely (active malignancy, pituitary conditions, and a few other contraindications), see tesamorelin peptide side effects. That's a companion piece and worth reading in full before starting treatment; this article isn't a substitute for a full safety review.

How does tesamorelin compare to other GH-related peptides in the evidence base?

Tesamorelin sits in a different evidence tier than most peptides marketed for similar goals. It has FDA approval backed by two pooled phase 3 randomized controlled trials with CT-measured endpoints ^[4]. Most other GHRH analogues and GH secretagogues circulating in the peptide space don't have anything comparable. A 2026 review in the Journal of the American Academy of Orthopaedic Surgeons looked at therapeutic peptides broadly across orthopaedic applications and flagged the gap between compounds with strong trial support and those without ^[15]. A companion piece in The American Journal of Sports Medicine, aimed at orthopaedic and sports medicine physicians, works through the practical issues of injectable peptide use in that setting, including where the evidence is thin ^[1]. A 2026 Sports Medicine review specifically assessed safety and efficacy across both approved and unapproved peptide therapies used for musculoskeletal injuries and athletic performance, a useful frame for understanding where tesamorelin sits relative to the wider unregulated peptide market ^[16]. | Compound | Regulatory status | Primary trial evidence |

Is tesamorelin legal to buy as a compounded product, and does that affect the evidence question?

Tesamorelin the approved drug (Egrifta) is one thing. Compounded tesamorelin, made by a 503A or 503B pharmacy from bulk peptide, is a separate regulatory and evidence question. Bulk drug substances used in 503A compounding are governed by 21 CFR 216.23 , and the 503B outsourcing facility bulk list is a separate regulation under 21 CFR 216.24 . Pharmacy compounding generally is authorized under 21 U.S.C. 353a . The FDA maintains a nominated bulk drug substances list for compounding review , and a working list of substances used in 503A compounding . None of that changes what the phase 3 trials showed. It changes where and how a person might obtain tesamorelin, and whether the specific product they receive has gone through the same manufacturing and quality process as the approved Egrifta product. If you're weighing cost against sourcing route, our tesamorelin cost breakdown covers pricing across the approved product and compounded alternatives, and where a provider-reviewed route through Tesamorelin Co connects patients to pharmacy partners fits into that picture.

What does the evidence NOT show?

This is worth stating directly, because it's where most of the confusion happens. The phase 3 trials enrolled HIV patients with lipodystrophy and excess abdominal fat. They did not enroll otherwise healthy adults seeking general fat loss, athletes seeking performance benefits, or older adults seeking anti-aging GH support. A 2013 review on growth hormone in the aging male discusses the broader GH axis and aging, but that's a separate literature from the tesamorelin-specific lipodystrophy trials, and it doesn't establish tesamorelin as an anti-aging treatment ^[17]. There's no phase 3 randomized trial establishing tesamorelin's effect on visceral fat in HIV-negative adults at anything close to the scale of the approval trials. The drug testing and detection literature is also worth flagging for a different reason: a 2021 review in Drug Testing and Analysis covers methods for detecting GHRH synthetic analogues, which matters for anyone in a tested sport, since tesamorelin and related GHRH analogues are performance-enhancing substances under anti-doping rules, more than supplements ^[18]. So the honest summary: strong, specific evidence for one narrow use. Off-label use might have a plausible mechanistic rationale, but plausible mechanism is not the same as trial evidence, and readers should treat the gap seriously rather than assuming the approval halo covers broader claims.

How should someone weigh this evidence when deciding whether to try tesamorelin?

If you have HIV-associated lipodystrophy with excess visceral fat, the evidence is about as solid as peptide therapeutics get: two pooled phase 3 randomized controlled trials, an FDA approval, a defined ~18% relative VAT reduction, and a real safety extension dataset ^[4][5]. That's a legitimate, well-supported clinical decision to make with a prescriber. If you don't have HIV and you're interested in visceral fat reduction or general GH support, you're in off-label territory with a much thinner evidence base specific to your situation. That's not automatically disqualifying, plenty of off-label prescribing is reasonable, but it means you should expect more individual variability, less certainty about magnitude of effect, and a genuine conversation with a prescriber about monitoring (glucose, IGF-1, injection site issues) rather than treating this as a settled question. Start with a real look at the tesamorelin overview page if you want the full mechanism and indication picture, then move to dosage and safety pages before deciding anything. A provider-reviewed pathway, the kind Tesamorelin Co connects patients through, exists specifically so a clinician evaluates your situation against this evidence rather than you self-interpreting a phase 3 trial designed for a different population.

Frequently asked questions

What percentage of visceral fat does tesamorelin reduce?

In the pooled phase 3 trials for HIV-associated lipodystrophy, tesamorelin reduced visceral adipose tissue by roughly 18% relative to placebo over 26 weeks, measured by CT scan ^[24]. This is the figure the FDA approval rests on. It applies specifically to that trial population, not to general fat loss in HIV-negative adults.

Is tesamorelin FDA-approved for weight loss?

No. Tesamorelin (Egrifta) is FDA-approved only for reducing excess visceral abdominal fat in HIV patients with lipodystrophy ^[2]. It is not approved as a general weight-loss drug, and there's no phase 3 trial establishing that use in people without HIV.

Does tesamorelin help with liver fat or fatty liver disease?

A randomized, double-blind trial in The Lancet HIV found tesamorelin reduced liver fat content in HIV patients with NAFLD ^[20], and a separate study linked visceral fat reduction to improved liver enzymes ^[19]. This is a research signal in HIV patients, not an FDA-approved indication for NAFLD generally.

How long does it take to see results from tesamorelin?

The core phase 3 trials measured visceral fat change at 26 weeks using CT scans ^[24]. That's the timeframe the approval evidence is built on. Individual response likely varies, and pharmacokinetic modeling shows real variability across patients in how tesamorelin is absorbed and cleared ^[21].

Does tesamorelin still work for people on newer HIV medications like integrase inhibitors?

A 2024 study in AIDS specifically evaluated tesamorelin's efficacy and safety in people with HIV on integrase inhibitor-based regimens ^[6], since these newer drugs carry a different metabolic and weight-gain profile than older regimens. This is the most directly relevant study for that combination.

What are the main side effects reported in tesamorelin trials?

Injection site reactions are the most common issue reported in the phase 3 program and its safety extension ^[24]. Joint pain and swelling related to the GH axis also occur. Glucose metabolism needs monitoring given the mechanism. See our tesamorelin peptide side effects page for the full breakdown.

Is tesamorelin the same as human growth hormone?

No. Tesamorelin is a GHRH analogue, meaning it stimulates the pituitary to release the body's own growth hormone in a pulsatile pattern, rather than delivering GH directly ^[4]. This mechanism is thought to preserve more physiological feedback regulation than direct GH injection.

Can tesamorelin be used for anti-aging or in people without HIV?

That would be off-label use. The approval and the phase 3 trial evidence are specific to HIV-associated lipodystrophy ^[2]. A 2013 review discusses GH and aging broadly ^[22], but there's no equivalent phase 3 trial establishing tesamorelin's effect on visceral fat or aging outcomes in HIV-negative adults.

How is tesamorelin dosed in the clinical trials?

The trial and approved dose is 2 mg by subcutaneous injection once daily ^[24]. Daily injection is a real adherence burden compared to weekly peptide regimens. See our tesamorelin dosage guide for injection technique, timing, and practical handling.

Does tesamorelin reduce inflammation?

A 2011 AIDS study found that inflammatory markers dropped in HIV patients with excess abdominal fat treated with tesamorelin, and the reduction correlated with the degree of visceral fat loss ^[26]. This is a secondary finding tied to the fat reduction, not a separate anti-inflammatory mechanism.

What happens if I stop taking tesamorelin?

The phase 3 program's safety extension followed patients on continued therapy rather than focusing on discontinuation effects specifically ^[24]. Since the mechanism depends on ongoing GHRH stimulation, it's reasonable to expect visceral fat benefits aren't necessarily permanent without maintenance, though this hasn't been rigorously quantified in published trials.

How does compounded tesamorelin relate to the approved drug's evidence?

The phase 3 trial evidence applies to the approved Egrifta product. Compounded tesamorelin is regulated separately under bulk drug substance rules (21 CFR 216.23 for 503A, 21 CFR 216.24 for 503B) ^[30][31], and compounding pharmacies operate under 21 U.S.C. 353a ^[32]. The trial data doesn't automatically validate every compounded formulation's quality or exact effect.

Sources

1. Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews, 2026 (PMID 41490200): Review of therapeutic peptides in orthopaedics flags evidence gaps between approved and unapproved compounds.
2. The American Journal of Sports Medicine, 2026 (PMID 41476424): Primer for orthopaedic and sports medicine physicians on injectable peptide therapy and evidence quality.
3. Nature Reviews Drug Discovery, 2011 (PMID 21283099): Tesamorelin works as a GHRH analogue stimulating pituitary GH release rather than delivering GH directly.
4. Sports Medicine (Auckland, N.Z.), 2026 (PMID 41966639): Review of safety and efficacy of approved versus unapproved peptide therapies for musculoskeletal and athletic use.
5. AIDS (London), 2024 (PMID 38905488): Study evaluated tesamorelin efficacy and safety in people with HIV on integrase inhibitor-based regimens.
6. Drug Testing and Analysis, 2021 (PMID 34665524): Review covers detection methods for GHRH synthetic analogues relevant to anti-doping testing.
7. The Journal of Infectious Diseases, 2025 (PMID 39813152): Study examined tesamorelin's effects on neurocognitive impairment in people with HIV and abdominal obesity.
8. JCI Insight, 2020 (PMID 32701508): Study mapped hepatic transcriptomic signatures following tesamorelin treatment in HIV-associated NAFLD.
9. The Journal of Clinical Endocrinology and Metabolism, 2022 (PMID 35137140): Review of lipodystrophy diagnosis and management discusses monitoring needs including glucose metabolism.
10. AIDS (London), 2021 (PMID 33756511): Tesamorelin improved adipose tissue quality independent of total fat mass changes.
11. Obesity Research & Clinical Practice, 2026 (PMID 41545261): Meta-analysis of RCTs confirms tesamorelin's effects on body composition, hepatic fat, metabolic and safety outcomes.
12. Scientific Reports, 2021 (PMID 34006921): Proteomic and transcriptomic analysis traced biological pathways behind tesamorelin's liver fat response.
13. AIDS (London), 2017 (PMID 28832410): Visceral fat reduction with tesamorelin was associated with improved liver enzymes in HIV patients.
14. The Lancet HIV, 2019 (PMID 31611038): Randomized double-blind trial found tesamorelin reduced liver fat content in HIV-associated NAFLD.
15. Clinical Pharmacokinetics, 2015 (PMID 25358450): Population pharmacokinetic analysis characterized tesamorelin exposure variability across HIV-infected and healthy subjects.
16. Best Practice & Research Clinical Endocrinology & Metabolism, 2013 (PMID 24054930): Review discusses growth hormone and aging as a separate literature from tesamorelin lipodystrophy trials.
17. Journal of Clinical and Translational Science, 2023 (PMID 36845310): Post hoc phase 3 analysis found tesamorelin effects held in patients with and without dorsocervical fat.
18. The Journal of Clinical Endocrinology and Metabolism, 2010 (PMID 20554713): Pooled phase 3 trial analysis found approximately 18% relative visceral fat reduction versus placebo over 26 weeks with 2 mg daily dosing.
19. AIDS (London), 2011 (PMID 21516030): Inflammatory markers decreased in HIV patients on tesamorelin, correlating with degree of visceral fat reduction.
20. eCFR, 21 CFR 216.23: Defines the bulk drug substances list governing 503A pharmacy compounding.
21. eCFR, 21 CFR 216.24: Defines the bulk drug substances list governing 503B outsourcing facility compounding.
22. Cornell Law, 21 U.S.C. 353a: Establishes the federal legal framework authorizing pharmacy compounding.
23. FDA, Bulk Drug Substances Used in Compounding Under Section 503A: FDA maintains and updates the working list of substances used in 503A compounding.
24. FDA, Bulk Drug Substances Nominated for Use in Compounding: FDA maintains a nominated bulk drug substances list under review for compounding use.